jain.com

Q3 2026 revenue guidance

Company: CoreWeave

Subject kind
guidance
Statement date
2026-08-14
Promised by
2026-09-30
Promised amount
3.45 USD
Current status
outcome unconfirmed

What the later record shows

Outcome not yet confirmed

No passage reports CoreWeave's actual Q3 2026 revenue. The evidence covers only Q2 results and full-year guidance.

Checked October 11, 2026 against filings, releases and reporting published after the claim was made. Quotes are verbatim from the linked documents.

The claim, verbatim

CoreWeave expects third-quarter 2026 revenue of $3.45 billion to $3.6 billion

Source (primary)

Coreweave Stock Is Back in Rally Mode. How CRWV Can Reclaim Its $153.20 High. - Yahoo Finance (-, news_article)
View cached copy (2026-08-31)Live source ↗

Quote: “Management expects third-quarter revenue of $3.45 billion to $3.6 billion”

How we checked this

Checked on October 2, 2026. The cited source supports every part of this claim.

The article states that management expects third-quarter revenue of $3.45 billion to $3.6 billion. Its August 2026 date and year-over-year comparisons place that quarter in 2026.

Confirmed in the source:

What we did: Read our cached copy of the publisher (https://finance.yahoo.com/markets/stocks/articles/coreweave-stock-back-rally-mode-160044388.html) in full (11,996 characters, retrieved August 31, 2026) and checked each assertion in the claim against it.

Additional evidence

confirms Coreweave Stock Is Back in Rally Mode. How CRWV Can Reclaim Its $153.20 High. - Yahoo Finance

Quote: “Management expects third-quarter revenue of $3.45 billion to $3.6 billion”

View cached copy (2026-08-31)Live source ↗

Record of changes

September 5, 2026 — stated
Automated extraction from the cited source. Recorded automatically from the cited source when it was published, then queued for evidence review.
October 1, 2026 — outcome unconfirmed
Automated extraction from the cited source. Recorded automatically from the cited source when it was published, then queued for evidence review.